Labeling of Orally Ingested Over-the-Counter Drug Products Containing Calcium, Magnesium, and Potassium; Correction

Riepilogo

The Food and Drug Administration (FDA) is correcting a notice of proposed rulemaking that appeared in the Federal Register of April 22, 1996 (61 FR 17807). The document proposed to amend the general labeling provisions for over-the-counter (OTC) drug products intended for oral ingestion to require the content per dosage unit and warning labeling when the product contains certain levels of calcium, magnesium, or potassium. The document was published with some errors. This document corrects those errors. DATES: Written comments by July 22, 1996. Written comments on the agency's economic impact determination by July 22, 1996. The agency is proposing that any final rule based on this proposal be effective 12 months after the date of its publication in the Federal Register. FOR FURTHER INFORMATION CONTACT: William E. Gilbertson, Center for Drug Evaluation and Research (HFD-105),- Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-2304. In FR Doc. 96-9734, appearing on page 17807 in the Federal Register of Monday, April 22, 1996, the following corrections are made: 1. On page 17808, in the third column, in the third full paragraph, in the seventh line, ``vitami